Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV
This study is currently recruiting participants.
Verified by National Institute of Mental Health (NIMH), January 2008
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00339092
  Purpose

This study will evaluate the effectiveness of a modified directly observed therapy program in increasing antiretroviral therapy adherence in poor, HIV-infected residents of urban communities.


Condition Intervention
HIV Infections
Behavioral: Modified Directly Observed Therapy
Behavioral: Standard Care

MedlinePlus related topics: AIDS
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Project Title: A RCT of HIV Adherence Case Management and Modified Directly Observed Therapy

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • CD4 and Viral Load [ Time Frame: Measured at baseline and Months 3, 6, and 9 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adherence [ Time Frame: Measured monthly for 9 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: January 2003
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Treatment: Experimental
Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
Behavioral: Modified Directly Observed Therapy
Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
Control: Active Comparator
Participants who receive standard of care
Behavioral: Standard Care
Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.

Detailed Description:

Antiretroviral drug therapy (ART) is a type of medication treatment for HIV that impairs the virus's ability to multiply. When used properly, it has been shown to be successful in reducing HIV-related deaths. A 95% adherence rate to ART is required to adequately suppress the virus and prevent transmission. High rates of mental illness, substance use, and unstable housing, however, make adherence to ART particularly problematic in poor urban populations. Directly observed therapy (DOT), in which medication intake is closely monitored, improved treatment adherence during the tuberculosis epidemic of the 1990s, and is now gaining recognition as a model for improving ART adherence. HIV DOT has been successfully delivered to people residing in structured living settings. The majority of HIV-infected people, however, live outside these facilities. Therefore, there is a need for a modified version of DOT to reach HIV-infected people in community settings. This study will evaluate the effectiveness of a MDOT program in increasing ART adherence in poor, HIV-infected residents of urban communities.

Participants in this open label study will be randomly assigned to either receive standard care or participate in the MDOT program. Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. If an individual does not attend a visit, study staff will try to locate the individual in the neighborhood to deliver the medication. Medication for the weekend will be prepared by study staff, but participants will take it on their own at home. At the end of 3 months, participants will no longer attend the study site for medication assistance. They will, however, participate in Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months. Participants will also check in with the study staff once a month. Following this, participants may choose to discontinue the Action Point program for the final 3 months of the study. They will continue monthly check-in visits with the study staff. At each visit, interviews will be conducted and medication adherence will be assessed. Blood tests will be performed once every 3 months throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV infected
  • Severely immunosuppressed (HIV viral load of greater than 400 copies/ml)
  • Does not consistently take prescribed ARV
  • Currently prescribed HIV medications or prescribed to start taking HIV medications

Exclusion Criteria:

  • Currently participating in any other adherence program or intervention study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00339092

Contacts
Contact: David R. Bangsberg, MD, MPH 415-206-4118 db@epi-center.ucsf.edu
Contact: Matthew D. Reynolds 415-476-2181 ext 2 mreynolds@epi-center.ucsf.edu

Locations
United States, California
UCSF Market Street Study Site Recruiting
San Francisco, California, United States, 94102
Contact: Matthew D. Reynolds     415-476-2181 ext 2     mreynolds@epi-center.ucsf.edu    
Principal Investigator: David R. Bangsberg, MD, MPH            
Sponsors and Collaborators
Investigators
Principal Investigator: David R. Bangsberg, MD, MPH University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco ( David R. Bangsberg, MD, MPH Prinicpal Investigator )
Study ID Numbers: R01 MH64388, DAHBR 9A-ASPG
Study First Received: June 16, 2006
Last Updated: January 2, 2008
ClinicalTrials.gov Identifier: NCT00339092  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
HIV
ART

Study placed in the following topic categories:
Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on January 14, 2009